Elsevier

Vaccine

Volume 15, Issue 5, April 1997, Pages 564-570
Vaccine

Paper
Development of an adjuvant-active nonionic block copolymer for use in oil-free subunit vaccines formulations

https://doi.org/10.1016/S0264-410X(97)00209-0Get rights and content

Abstract

Nonionic block copolymers, synthesized from repeating units of oxypropylene and oxyethylene, can be designed so that individual copolymers have unique physical properties with differential levels of adjuvant activity. We have designed high molecular weight block copolymers that spontaneously assemble into 500 nm–3 μm particles when formulated with protein antigens in aqueous solutions at physiological pH. The adjuvant activity of one of these copolymers, termed CRL1005, was compared to selected research adjuvants using ovalbumin (OVA) as the prototype vaccine antigen. Suboptimal doses of OVA were formulated with complete and incomplete Freund's adjuvant (CFAIFA), alum, Quil-A saponins, Ribi Adjuvant System (RAS) or the CRL1005 copolymer and these formulations were used to immunize C57BL6 mice. The CRL1005 copolymer appeared to be more potent than either Quil-A or alum and comparable to the RAS formulation, based on the numbers of responding mice and the OVA-specific antibody titers. Alum, RAS and Quil-A all augmented the production of IgG1 and IgG2b similarly whereas only the CFAIFA boosted IgG2a levels significantly. The effect of adjuvants on relative antibody affinity was more variable with the CRL1005 and CFAIFA inducing antibodies with the highest affinity scores. This high molecular weight nonionic copolymer is nontoxic in aqueous formulations and should therefore be compatible with a wide variety of protein or polysaccharide vaccine antigens.

References (47)

  • C. Damais et al.

    In vitro spleen cell responsiveness to various analogs of MDP (N-acetylmuramyl-l-isoglutamine), a synthetic immunoadjuvant, in MDP high-responder mice

    Cell. Immunol.

    (1978)
  • A. Tanaka et al.

    Stimulation of the reticuloendothelial system of mice by muramyl dipeptide

    Infect. Immun.

    (1976)
  • I. Gery et al.

    Stimulation of B-lymphocytes by endotoxin. Reactions of thymus-deprived mice and karyotypic analysis of dividing cell in mice bearing T6T6 thymus grafts

    J. Immunol.

    (1972)
  • A.G. Johnson et al.

    A study of the cellular and molecular mediators of the adjuvant action of a nontoxic monophosphoryl lipid A

    Adv. Exp. Med. Biol.

    (1990)
  • M.A. Tomai et al.

    T cell and interferon-gamma involvement in the adjuvant action of detoxified endotoxin

    J. Biol. Response Modifiers

    (1989)
  • W.P. Arend et al.

    Characteristics of bacterial lipopolysaccharide induction of interleukin 1 synthesis and secretion by human monocytes

    Clin. Exp. Immunol.

    (1986)
  • C.R. Kensil et al.

    Separation and characterization of saponins with adjuvant activity from Quillaja saponaria molina cortex

    J. Immunol.

    (1991)
  • V.E.C.J. Schijns et al.

    Modulation of antiviral immune responses by exogenous cytokines: effects of tumour necrosis factor-α, interleukin-1α, interleukin-2 and interferon-gamma on the immunogenicity of an inactivated rabies vaccine

    J. Gen. Virol.

    (1994)
  • L.C.C. Alfonso et al.

    The adjuvant effect of interleukin-12 in a vaccine against Leishmania major

    Science

    (1994)
  • A.D. Nash et al.

    Recombinant cytokines as immunological adjuvants

    Immunol. Cell Biol.

    (1993)
  • A. Nohria et al.

    Cytokines as potential vaccine adjuvants

    Biotherapy

    (1994)
  • R.K. Gupta et al.

    Adjuvant properties of aluminum and calcium compounds

  • G. Ott et al.

    MF59: Design and evaluation of a safe and potent adjuvant for human vaccines

  • Cited by (33)

    • Preparation and use of adjuvants

      2002, Methods in Microbiology
    View all citing articles on Scopus
    View full text